AI-extracted from the 10-Q filed 2026-08-13 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Clinical-stage biotech with $133.3M cash reported zero revenue in Q2 2026 but advanced pipeline: ozekibart BLA filed for chondrosarcoma, INBRX-106 Phase 2 data positive in HNSCC with 44% ORR.
Biggest Revenue Drivers
License fee revenue$0M-100% YoY
No revenue recognized in Q2 2026; prior year Q2 2025 revenue of $1.3M from Scithera License Agreement completion was non-recurring.
Biggest Revenue Drivers
Total revenue: $0M
License fee revenue$0M-100% YoY
No revenue recognized in Q2 2026; prior year Q2 2025 revenue of $1.3M from Scithera License Agreement completion was non-recurring.
Largest Expense Items
Research and development$23.9M+7% YoY
Increased due to contract manufacturing (+$1.6M for ozekibart and INBRX-106 activities, including BLA filing support) and clinical trial costs (+$1.2M from trial progression), partially offset by reduced personnel costs (-$0.6M from headcount decrease).
General and administrative$8.3M+28% YoY
Increased primarily by pre-commercialization expenses (+$1.6M for market access, launch strategy, and communication materials for ozekibart) and higher stock-based compensation.
Interest expense$5.7M+81% YoY
Higher debt outstanding: $175.0M principal in Q2 2026 (post-March 2026 Amendment) versus $100.0M in Q2 2025, including non-cash amortization of debt discount and final payment fee.
Margins: Company is pre-revenue and unprofitable. Operating loss was $32.1M in Q2 2026 versus $27.4M in Q2 2025. No gross margin applicable as no product sales. Operating expense increase moderated by R&D efficiencies from prior trial completion, but G&A grew as commercialization efforts expanded.
Watch Items from the Filing
Accumulated deficit reached $316.3M as of June 30, 2026. Company projects existing cash of $133.3M sufficient for ≥12 months; substantial additional funding required for commercial launch and continued development.
Long-term debt of $176.3M (net of discount) under Amended 2025 Loan Agreement matures January 2030. Interest-only through February 2028, then principal repayment begins; $15.75M final payment fee at maturity.
Ozekibart (INBRX-109) BLA filed June 2026 for chondrosarcoma; FDA cleared Phase 1/2 partial hold in April 2023 after hepatotoxicity incident. Form 483 observations issued during FDA inspections; corrective actions implemented but timeline risk remains.
INBRX-106 Phase 2 HexAgon study in HNSCC showed 44% ORR in combination arm vs. 21.4% with pembrolizumab alone (n=25 and n=28 evaluable); Phase 3 initiation planned Q3 2026.
July 15, 2026 subsequent event: Second Amendment to Loan Agreement with Oxford provides up to $325.0M additional funding ($100.0M funded immediately as Term C Loan; $225.0M optional Term D Loan in $50M+ increments at lender discretion).
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Vuori Kristiina MDDirectorGrant or award · Jun 3, 2026
Matly DavidPresidentGrant or award · Apr 24, 2026
About Inhibrx Biosciences, Inc. (INBX): stock profile, AI score and financials
Inhibrx Biosciences, Inc. (INBX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INBX at 29.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,455 of 2,888 stocks — the bottom half of the AI-ranked universe. INBX scores in the top quartile across revenue growth (95.4), institutional flow (90.0). Areas of concern include free cash flow (0.4) and revenue scale (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Inhibrx Biosciences, Inc. reports net income of $-36.6M, free cash flow of $-29.9M. Top institutional holders of INBX by reported 13-F value include MORGAN STANLEY, PERCEPTIVE ADVISORS, Sanofi, based on the most recent SEC filings. INBX trades on the Nasdaq exchange and files with the SEC under CIK 2007919. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INBX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inhibrx Biosciences, Inc. directly from SEC EDGAR.